Middle East And Africa Veterinary Pharmaceutical Drugs Market Size & Outlook, 2025-2033
Middle East And Africa Veterinary Pharmaceutical Drugs Market Insights
- As per Reed Intelligence insights, Middle East And Africa’s Veterinary Pharmaceutical Drugs Market was valued at USD 5676.45 Million in 2024 and is anticipated to expand to USD 10516.5 Million by 2033.
- From 2025 to 2033, the market is anticipated to expand at a CAGR of 7.09%.
- Within By Animal Type, Production accounted for the largest market size in 2024.
- During the forecast period, Companion is anticipated to remain the highest-growth segment within the By Animal Type category.
Source: RI Analysis Company Publications, Primary Interviews.
Other Key Findings
- The global Veterinary Pharmaceutical Drugs Market size saw Middle East And Africa holding a share of 10.66% in 2024.
- United States is forecasted to account for the leading share of the global market by 2033.
- In Middle East and Africa, Saudi Arabia is forecasted to be the fastest-expanding market, projected to reach USD 2036.85 Million by 2033.
Report Summary
| Report Scope | Details |
|---|---|
| Base Year for Study | 2024 |
| Study Period | 2021-2033 |
| Historical Period | 2021-2023 |
| Forecast Period | 2025-2033 |
| Market Size In 2024 | USD 5676.45 Million |
| Market Size In 2033 | USD 10516.5 Million |
| Largest segment | Production |
| Units | Revenue in USD Million |
| CAGR | 7.09% (2025-2033) |
| Segmnetation Covered | |
| Middle East and Africa |
|
| By Animal Type |
|
| By Product Type |
|
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, Environment & Regulatory Landscape and Trends |
Middle East And Africa Veterinary Pharmaceutical Drugs Market Country 2025-2033 (USD Million)
| Middle East and Africa | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Arab Emirates | XX.x | XX.x | XX.x | 2689.5 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Saudi Arabia | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| South Africa | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Egypt | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Nigeria | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Turkey | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Middle East And Africa Veterinary Pharmaceutical Drugs Market By Animal Type 2025-2033 (USD Million)
| By Animal Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Production | XX.x | XX.x | XX.x | 3126.59 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Companion | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
Middle East And Africa Veterinary Pharmaceutical Drugs Market By Product Type 2025-2033 (USD Million)
| By Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Biologics | XX.x | XX.x | XX.x | 2564.05 | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Pharmaceuticals | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Medicated Feed Additives | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
| Total | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x | XX.x |
Source: RI Analysis Company Publications, Primary Interviews.
